Thomas Schuetz
Vorstandsvorsitzender bei COMPASS THERAPEUTICS, INC.
Vermögen: 8 Mio $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Vered Bisker-Leib | M | 53 |
Compass Therapeutics LLC
 Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | 7 Jahre |
| Jonathan Silverstein | M | 57 |
Arteaus Therapeutics LLC
 Arteaus Therapeutics LLC BiotechnologyHealth Technology Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA. | 8 Jahre |
| Carl Gordon | M | 59 |
Compass Therapeutics LLC
Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | 9 Jahre |
| Phil Ferneau | M | 62 |
Compass Therapeutics LLC
Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | 9 Jahre |
| Kush Parmar | M | 42 | 11 Jahre | |
| Jean-Francois Leprince | M | - |
GLyPharma Therapeutic, Inc.
 GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | - |
| Mary Gray | M | 71 | 2 Jahre | |
| Ellen Chiniara | F | 65 | 2 Jahre | |
| Jonathan Anderman | M | - | 3 Jahre | |
| Richard Lindahl | M | 70 | 1 Jahre | |
| James Boylan | M | 57 | 2 Jahre | |
| Anna Gifford | F | - | 3 Jahre | |
| Nicole Blijlevens | F | - |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | - |
| Aleksandr Lazaryan | M | - |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | - |
| Minori Rosales | M | 61 | 1 Jahre | |
| Fulvio Mavilio | M | - | 7 Jahre | |
| Pierre LaPalme | M | 83 |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | 12 Jahre |
| Ian Chia | M | - | 6 Jahre | |
| Gaétan Gravel | M | - |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | - |
| Michael Seckler | M | 59 |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | - |
| Neil Lerner | M | 56 | 4 Jahre | |
| Ken Pastor | M | - |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | - |
| Jennifer Foley | F | - |
Arteaus Therapeutics LLC
Arteaus Therapeutics LLC BiotechnologyHealth Technology Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA. | - |
| Karin Herrera | F | - | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Stephen P. Squinto | M | 67 |
Compass Therapeutics LLC
Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | 7 Jahre |
| Matt Patterson | M | 52 | 8 Jahre | |
| Thomas Soloway | M | 55 | - | |
| Gerrit Klaerner | M | 53 | 6 Jahre | |
| Natalie Holles | F | 51 | 6 Jahre | |
| Errik B. Anderson | M | - |
Compass Therapeutics LLC
Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | - |
| Charlotte Arnold | F | - | - | |
| John Orwin | M | 59 | 4 Jahre | |
| Julie Smith | F | 53 |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 9 Jahre |
| Julie Sunderland | F | 51 |
Compass Therapeutics LLC
Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | 2 Jahre |
| Patrick Treanor | M | - | - | |
| Miranda Toledano | F | 47 | 1 Jahre | |
| Kenneth Hillan | M | 63 | 2 Jahre | |
| Eric Trachtenberg | M | 51 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 Jahre |
| Wilhelm Stahl | M | 64 | 6 Jahre | |
| Brett Ilan Kaplan | M | 50 | 2 Jahre | |
| Steven Tregay | M | - |
Compass Therapeutics LLC
Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | - |
| Helen Sabzevari | M | 62 |
Compass Therapeutics LLC
Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | 2 Jahre |
| Thomas Woiwode | M | 52 | 4 Jahre | |
| Edward Conner | M | 51 | 2 Jahre | |
| Claire J. Lockey | F | 71 | 5 Jahre | |
| Jennifer Jarrett | F | 53 | 3 Jahre | |
| Scott Morrison | M | 66 | 5 Jahre | |
| Mark Goldberg | M | 69 | 3 Jahre | |
| Louis Lange | M | 72 | 5 Jahre | |
| Jonathan Leff | M | 55 | - | |
| Dan Spiegelman | M | 65 | 2 Jahre | |
| David Wurzer | M | 65 | - | |
| Scott Rocklage | M | 69 | 7 Jahre | |
| J. Garland | M | 55 | 4 Jahre | |
| Paul Hastings | M | 64 | 4 Jahre | |
| Helen Torley | M | 61 | 1 Jahre | |
| David McGirr | M | 69 | 3 Jahre | |
| Ron Hunt | M | 59 | 2 Jahre | |
| John Butler | M | 59 | 3 Jahre | |
| Jerry M. Buysse | M | 68 | 6 Jahre | |
| Lynne Sullivan | F | 58 |
Compass Therapeutics LLC
Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | 1 Jahre |
| Jebediah Ledell | M | 49 |
Compass Therapeutics LLC
Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | 2 Jahre |
| Abbey Jenkins | F | - | 2 Jahre | |
| Steven Hill | M | 53 | 6 Jahre | |
| Uciane Scarlett | M | - | 2 Jahre | |
| Alain Romero | M | - | - | |
| Laurie Hastings | F | - | 5 Jahre | |
| Toru Yoshimitsu | M | 61 | - | |
| Zane Rogers | M | - | - | |
| Susan Kalled | M | - | 1 Jahre | |
| Donald Wuchterl | M | 54 | 5 Jahre | |
| Deborah Sim | F | - | - | |
| Tracy M. Porter | F | - | 1 Jahre | |
| Todd Ungard | M | - | - | |
| John Gustofson | M | - |
Therion Biologics Corp.
 Therion Biologics Corp. Pharmaceuticals: MajorHealth Technology Therion Biologics Corp. developed therapeutic vaccines for cancer patients. The company was founded on May 5, 1991 and was headquartered in Cambridge, MA. | 2 Jahre |
| James Shahbazian | M | - | - | |
| Kristine Ball | M | 52 | 4 Jahre | |
| Suyash Prasad | M | 54 | 5 Jahre | |
| Richard Woodrich | M | 76 |
Therion Biologics Corp.
Therion Biologics Corp. Pharmaceuticals: MajorHealth Technology Therion Biologics Corp. developed therapeutic vaccines for cancer patients. The company was founded on May 5, 1991 and was headquartered in Cambridge, MA. | 5 Jahre |
| Jason Barker | M | 54 | - | |
| Lance Berman | M | 53 | - | |
| Deepa Pakianathan | M | 59 | 5 Jahre | |
| Mario Corso | M | - | - | |
| David Nagler | M | 71 | 5 Jahre | |
| Stephen D. Harrison | M | 59 | - | |
| Mary E. Corbett | F | 72 | - | |
| Sylvia R. Wheeler | F | 63 | - | |
| James Johnson | M | 67 | 1 Jahre | |
| Erin E. Lanciani | F | 55 |
Therion Biologics Corp.
Therion Biologics Corp. Pharmaceuticals: MajorHealth Technology Therion Biologics Corp. developed therapeutic vaccines for cancer patients. The company was founded on May 5, 1991 and was headquartered in Cambridge, MA. | 4 Jahre |
| Mary Reumuth | F | 48 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 Jahre |
| Klaus Veitinger | M | 62 | 5 Jahre | |
| Titus M. F. M. Plattel | M | - |
Therion Biologics Corp.
Therion Biologics Corp. Pharmaceuticals: MajorHealth Technology Therion Biologics Corp. developed therapeutic vaccines for cancer patients. The company was founded on May 5, 1991 and was headquartered in Cambridge, MA. | 2 Jahre |
| Andreas Stefan Walde | M | 62 | - | |
| Yip-Fong Chia | F | - | - | |
| Jeffrey C. Mack | M | - |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | - |
| Sarah Spencer | F | - | 2 Jahre | |
| Jennifer Chung | F | - | - | |
| Oliver P. Kronenberg | M | - | - | |
| John T. Gray | M | 60 | 5 Jahre | |
| I-Zu Huang | M | - | 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 90 | 90,00% |
| Kanada | 11 | 11,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Thomas Schuetz
- Persönliches Netzwerk
